| Name | Title | Contact Details |
|---|
AIMSCO is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2005, ZELTIQ is a global medical technology company that developed its patented, non-invasive, and clinically proven CoolSculpting Procedure to selectively reduce exercise-resistant fat bulges.
Recovery Force is an innovative medical device company providing healthcare professionals, patients, and athletes with a next-generation mobile compression solution for enhancing circulation. The company has developed a platform technology with the ability to embed shape-changing memory fibers into various types of garments and footwear to produce therapeutic compressions. Recovery Force`s portfolio includes medical devices that will reduce post-operative pain, swelling and wound healing time; treat chronic lymphedema; prevent blood clots (DVT); and alleviate joint pain and sore muscles. The same technology used in healthcare is also available to sports enthusiasts and athletes, providing enhanced circulation during warm-up and recovery to achieve optimal performance.
PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.